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ABSTRACT 
 
The mdm2 gene encodes several protein isoforms with different molecular weights (p90, p80, p76 and p57). 
MDM2 p90 (usually considered to be the major MDM2 protein) binds to and inactivates P53. We have re-
cently shown that growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with 
P53 down-regulation. In this work, we analyzed the expression pattern of MDM2 proteins in three human 
breast cancer cell lines by western blotting with anti-MDM2 antibodies. We found a prominent expression of 
MDM2 p57 protein in cell lines which have non-functional P53 protein (T47D and MDA-MB-231) as com-
pared to the p90, p80 isoforms, whereas p90 was the major protein isoform in MCF-7 cells that contain func-
tional P53 protein. When MCF-7 cells were treated with 100 nM of progesterone, MDM2 p90 was inhibited 
but the highly expressed MDM2 p57 isoform was not. The inhibition of MDM2 p90 protein by progesterone 
was abrogated in MCF-7 cells transfected with a P53 expressing vector. To our knowledge, this is the first 
report linking progesterone-induced growth inhibition with down-regulation of the MDM2 protein. We pre-
sent evidence that reestablishing of P53 expression by transient transfection of P53 cDNA in these cells en-
hances the expression level of MDM2 p90 isoform. The data indicate that expression of MDM2 p90 is regu-
lated through a P53-dependent pathway in response to progesterone.  
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INTRODUCTION 
 
The  mdm2  gene  was  originally  cloned  as  an  amplified 
gene on a murine double-minute chromosome in the tu-
morigenic  3T3DM  murine  cell  line  (Fakharzadeh  et  al, 
1991).  The  corresponding  human  mdm2  gene  was  also 
subsequently identified  (Oliner  et al,  1992).  MDM2  ex-
pression is controlled at the transcriptional level from P53-
independent  (P1)  and  P53-responsive  (P2)  promoters 
(Zauberman  et  al,  1995),  both  encoding  a  90  kDa  full 
length MDM2 (p90) protein (Brown et al, 1999). In addi-
tion, MDM2 proteins of smaller sizes have been identified 
(Olson et al, 1993; Perry et al, 2000; Bartel et al, 2002). 
These differently sized proteins arise through either prote-
olytic cleavage (Pochampally et al, 1998), internal transla-
tional initiation (Saucedo et al, 1999) or alternative splic-
ing (Sigalas et al, 1996; Matsumoto, 1998). Although the 
biochemical functions of these small proteins have not yet 
been  determined,  the  MDM2-p90  isoform  binds  to  and 
inactivates P53 tumor suppressor protein suggesting that 
MDM2 can function as a negative feed-back regulator of 
P53 (Momand et al, 1992; Barak et al, 1993). Lukas et al 
(2001) suggested that MDM2 expression is altered in inva-
sive breast cancer and is associated with more aggressive 
disease. We have recently demonstrated that the proges-
terone-induced  growth  inhibition  of  the  MCF-7  human 
breast  cancer  cell  line  was  associated  with  down-
regulation  of  P53  endogenous  levels  (Alkhalaf  and  El-
Mowafy, 2003). Because the regulation of MDM2 expres-
sion by P53 has been proposed by several authors to be the 
mechanism by which P53 balances its own activity (Juven 
et al, 1993; Midgley and Lane, 1997; Prives, 1998), we 
hypothesized that the decrease in P53 levels seen in MCF-
7 cells treated with progesterone would affect MDM2 ex- 
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pression. We report here that in MCF-7 human breast can-
cer cells  treated  with  progesterone,  MDM2  p90  but  not 
MDM2 p57 is  down-regulated. To confirm the involve-
ment of P53 in this down-regulation of MDM2, MCF-7 
cells were transiently  transfected  with a  P53  expression 
vector (Alkhalaf and El-Mowafy, 2003). Overexpression 
of P53 in MCF-7 cells stimulated the MDM2 expression 
and abrogated the effect of progesterone. The data suggest 
that  expression  of  MDM2  p90  is  regulated  via  a  P53-
dependent pathway in MCF-7 human breast cancer cells 
treated with progesterone. 
 
MATERIALS AND METHODS 
 
Cell lines and culture conditions 
The  breast  cancer  cell  lines  MCF7,  T47D,  and  MDA-
MB231  were  kindly  provided  by  Bohdan  Wasylyk 
(IGBMC Core Facility, Strasbourg, France). The MCF-7 
cells contain functional P53  protein localized at the  nu-
cleus (Wasylyk et al, 1999) and classified as progesterone 
and estrogen receptor positive. The T47D cells have a mu-
tated  type  of  P53  which  is  localized  in  the  cytoplasm 
(Schafer et al, 2000) and contain both estrogen and proges-
terone  receptors.  The  MDA-MB231  cells  have  non-
functional P53 protein (Toillon et al, 2002) and have no 
functional progesterone and estrogen receptors. The cells 
were grown in RPMI1640 medium (Gibco BRL) supple-
mented with 5% fetal bovine serum, glutamine and gen-
tamicin and maintained in a 5% CO2 humidified atmos-
phere in a 37 ºC incubator. 
 
Western Blot Analysis 
Cells were washed twice with PBS buffer then the pre-
heated (95ºC) lysis buffer [20 mM Tris-HCl pH 7.4, 20 
mM dithiothreitol (DTT), 2 mM EDTA (sodium salt), 1% 
(v/v) Triton X-100, 1% (v/v) NP40, 1% (w/v) sodium de-
oxycholate, 1 mM sodium pyrophosphate, 1 mM sodium 
orthovandate (prepared in Tris buffer) and 1 mM phenyl-
methylsulphonyl-fluoride] was added directly  to  the cell 
monolayer. The cells were scraped and mixed with a rub-
ber policeman, transferred to Eppendorf tubes and centri-
fuged at 13000 x g for 5 min. The resulting supernatant 
was saved and the protein was determined by the Bradford 
method. Extracts were boiled for 3 min in 2 x SDS buffer. 
Equal amounts of protein were loaded on 10% (w/v) poly-
acrylamide gels according to the method of Laemmli and 
then  electrotransferred  onto  nitro-cellulose  membranes. 
The  blots  were  incubated  first  with  anti-MDM2  (Ab-1, 
clone  IF2)  monoclonal  antibody  (Oncogene  Research 
Product, Calbiochem). The antibody is directed against the 
N-terminal fragment between amino acid residues 26-169 
of human MDM2 (Fakharzadeh et al, 1991) then incubated 
with  peroxidase-conjugated  anti-mouse  IgG  (Jackson 
Laboratory,  USA)  at  1/2000  dilution.  Immunoreactive 
bands were visualized by incubation with luminol (accord-
ing to manufacturer’s instructions; ECL Western blotting 
detection  system  from  Amersham).  The  blots  were 
stripped and hybridized with P53 (DO1) monoclonal anti-
bodies (Oncogene Research, Cambridge, MA, USA) and 
processed as for the MDM2 antibodies. The TATA- Bind-
ing  Protein  (TBP)  monoclonal  antibody  was  used  as  a 
loading control (kindly provided by IGBMC Core Facility, 
Illkirch,  France).  Another  MDM2  antibody  was  used, 
MDM2 (C-18) purchased from Santa Cruz Biotechnology 
(California,  USA).  It  is an affinity  purified rabbit  poly-
clonal antibody raised against a peptide mapping within 
the carboxyl terminal domain of MDM2 of human origin. 
A prestained SDS-PAGE molecular weight protein stan-
dards  (low  range)  is  used  to  estimate  the  molecular 
weights of proteins ((Bio-Rad, UK). 
 
Transient transfection of MCF-7 with P53 cDNA ex-
pression vector 
MCF-7 cells were maintained in RPMI1640 medium + 5% 
FBS + antibiotics at 37ºC with 5% (v/v) CO2 in 36 mm 
plates  (6-well  cluster,  Nunc,  Roskilde,  Denmark).  They 
were transfected either with 3 µg CMV expression vector 
(pcDNA3, obtained from Invitrogen, Paisley, UK ) or with 
3 µg CMV vector containing human P53 cDNA (kindly 
provided by the IGBMC core facility, Illkirch, France) by 
using  lipofectamine  (Gibco-BRL,  Paisley,  UK).  MCF-7 
cells  that  overexpress  P53  as  well  as  the  control  cells 
(transfected with the empty vector) were treated with vehi-
cle alone or with 100 nM of progesterone for 24 hr. The 
total protein extracts were prepared and tested with DO-1, 
IF2 and TBP monoclonal antibodies as indicated above. 
 
RESULTS 
 
Prominent expression of MDM2 p57 protein in human 
cancer cell lines 
The expression of MDM2 proteins in MCF7, T47D, and 
MDA-MB231 human breast cancer cell lines was analyzed 
by Western blotting with anti-MDM2 (Ab-1) monoclonal 
antibody.  Figure  1  shows  that,  with  this  antibody,  four 
MDM2  isoforms  were  detected,  the  p57,  p76,  p80,  and 
p90 kDa in all three cell lines.   A prominent expression of  
 
 
 
   
 
 
 
Figure 1. Endogenous levels of P53 and MDM2 isoforms in 
human breast cancer cell lines. Endogenous levels of MDM2 
proteins (p90, p80, p57) and P53 proteins in human breast cancer 
cell lines MDA-MB231 (lane 1); T47D (lane 2), MCF-7 (lane 3). 
100 µg of total protein extract were analyzed by 10% SDS-
PAGE, blotted on nitrocellulose membranes and probed with 
antibodies against MDM2 (IF2), P53 (DO1) and TBP (3G3). 
Four isoforms of MDM2 were detected and the most abundant is 
the p57 isoform. P53 protein was detected in all cell lines with 
different levels. TBP was used as a loading control since it shows 
the same level in all cell lines.  
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MDM2 p57 protein as compared to the p90, p80 or p76 
was  observed  in  the  three  cell  lines  used  in  this  study. 
MDM2 p90 protein level was dependent on p53 status in 
the  cells.  In  MCF-7  cells  that  contained  functional  P53 
protein,  the  endogenous  MDM2  p90  protein  level  was 
higher than these in T47D and MDA-MB 230 cell lines 
(both have mutated P53 proteins). In contrast, MDM2 p57 
appeared to be lower in MCF-7 as compared to its levels 
in the cells which have mutated P53. The high level of 
MDM2 p57 was observed in other breast cancer cells, a 
normal breast cell line and in other types of cancer cell 
lines (data not shown). 
 
Progesterone  inhibits  MDM2  p90  in  MCF-7  human 
breast cancer cell line 
The MCF-7 cell line was used in this experiment because 
it has high levels of the four MDM2 isoforms and because 
we had already shown that progesterone down-regulated 
P53  protein  in  these  cells  (Alkhalaf  and  El-Mowafy, 
2003). We investigated whether the P53 inhibition in this 
cell  line  would  affect  the  endogenous  levels  of  MDM2 
proteins. When MCF-7 cells are treated with 100 nM of 
progesterone, expression of p90 was specifically inhibited, 
unlike that of the highly expressed p57 isoform or the TBP 
protein (Figure 2). 
 
P53  Overexpression  stimulates  MDM2  expression  in 
MCF-7 human breast cancer cells 
The  observation  that  progesterone  simultaneously  inhib-
ited endogenous MDM2 (Figure 2) and P53 (Alkhalaf and 
El-Mowafy, 2003) in MCF-7 cells prompted us to check 
the consequences of re-establishing the P53 expression in 
the cells by exogenous expression using transient transfec-
tion experiments. MCF-7 cells were transfected with ex-
pression  vector  (3  µg/well)  for  CMV  vector  and  CMV 
vector  containing  human  P53  cDNA.  The  cells  were 
treated with vehicle or with 100 nM of progesterone for 24 
hr.  Western  blot  analysis  was  used  to  estimate  the  P53 
levels  achieved  by  transient  transfection.  CMV-  trans-
fected   MCF-7  without  progesterone  treatment   showed  
 
 
 
 
          
 
 
Figure 2. Inhibition of MDM2 p90 protein by progesterone in 
MCF-7 human breast cancer cells. MCF7 cells were cultured 
in 5% fetal bovine serum and treated with100 nM of proges-
terone, harvested at the indicated times. Cellular extracts (100 
µg) were analyzed by Western blots for levels of MDM2  (C-
18 antibody) and TBP (3G3). 
normal levels of P53, MDM2 p90 and MDM2 p57. When 
CMV-transfected MCF-7 cells were treated with 100 nM 
of progesterone, both MDM2 p90 and P53 were inhibited, 
unlike the MDM2p57 isoform.  MCF-7 cells transfected 
with CMV+P53 vector showed approximately three fold 
higher P53 levels than CMV transfected cells (Figure 3) as 
revealed  by  densitometry.  In  these  P53  overexpressing 
MCF-7 cells, the MDM2 p90 level was elevated to reach 
approximately the same level observed in the CMV trans-
fected  MCF7  cells  without  progesterone  treatment.  The 
increase in MDM2 p90 level in MCF-7 cells that overex-
press P53 is associated with progesterone treatment sug-
gesting  that  p53  reestablishing  p53  expression  enhances 
the  expression  of  MDM2  p90  and  that  this  increase  in 
MDM2 level is progesterone-dependent. 
 
 
 
              
 
 
Figure 3. The inhibition of MDM2 p90 protein by progesterone 
was abrogated in MCF-7 cells transfected with a p53 express-
ing vector: MCF-7 cells were transfected with expression vec-
tor (3 µg/well) for CMV vector and CMV vector containing 
human P53 cDNA. The cells were treated with vehicle or with 
100 nM of progesterone (P) for 24 hours. 20 µg of extracts 
were subjected to Western blotting analysis to determine the 
relative amounts of P53, MDM2 p90, MDM2 p57 and TBP 
(used as a loading control) proteins. MCF-7 cells transfected 
with CMV-P53 vector contained over three fold of P53 than 
CMV transfected cells. The cells showed increase in MDM2 
p90 but not in MDM2 p57 protein levels. The increase in the 
MDM2 p90 in response to P53 overexpression has the same 
magnitude observed in cells not treated with progesterone. 
 
 
 
DISCUSSION 
 
More  than  40  different  splice  variants  of  MDM2  tran-
scripts  have  been  identified  both  in  tumors  and  normal 
tissues (Gudas et al, 1995; Lukas et al, 2001; Bartel et al, 
2002; Phelps et al, 2003). At the protein level at least five 
MDM2  proteins  (p90,  p80,  p74/76,  p70,  p57/60)  have 
been  described  (Oslon  et  al,  1993;  Haider  et  al,  1997; 
Pochampally    et  al,  1998;  Pochampally    et  al,  1999; 
Saucedo  et  al,  1999;  Bartl  et  al,  2003).  It  was  demon-
strated that these differently-sized MDM2 isoforms may 
arise through either proteolytic cleavage (Pochampally et 
al, 1998), internal translational initiation (Saucedo et al, 
1999) or alternative splicing (Sigalas et al, 1996; Matsu-
moto et al, 1998). Although the biochemical functions of 
these proteins have  not  yet  been determined, their exis- 
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tence suggests that MDM2 may be involved in additional 
unknown functions. 
 
The expression of MDM2 is known to be induced by P53 
as Landers et al. 1997 demonstrated that the high level of 
mdm2  overexpression  in  human  tumor  cells  containing 
elevated levels of wild-type P53 resulted from enhanced 
translation at the  p53-responsive promoter region  of the 
mdm2  gene  (Landers  et  al,  1997).  Recent  evidence  has 
shown that MDM2 expression can also be regulated via 
P53-independent pathways (Phelps et al, 2003). Our data 
show that in cells with functional P53 proteins, endoge-
nous MDM2 p90 was the major MDM2 protein isoform 
and that cells with a mutated P53 gene showed very low 
levels of the MDM2 p90 protein. The present data show 
also  that  progesterone  down-regulates  the  endogenous 
level of MDM2 p90. This down-regulation of MDM2 p90 
may  be  associated  with  down-regulation  of  the  endoge-
nous P53 level observed in the same conditions (Alkhalaf 
and  El-Mowafy,  2003).  By  contrast,  re-establishing  the 
P53 endogenous expression in MCF-7 by transient expres-
sion led to elevation of MDM2 p90 indicating the possible 
involvement  of  the  P53  pathway  in  the  regulation  of 
MDM2 p90. 
 
Overexpression of the MDM2 proteins is often observed in 
breast  cancer  tissues  and  cell lines  (Sheikh  et  al,  1993; 
McCann  et al, 1995; Pinkas  et al, 1999). Bueso-Ramos et 
al (Bueso-Ramos et al, 1996) suggested that MDM-2 p57 
protein  represents  the  main  MDM-2  protein  altered  in 
breast carcinomas: they found MDM-2 overexpression in 
15  of  21  breast  carcinoma tissue  samples.  Ten  of  these 
fifteen cases overexpressed MDM2 p57 protein, while two 
cases  overexpressed  both  MDM2  p57  and  MDM2  p90, 
and three cases  overexpressed only MDM2  p90.   How-
ever, the status of the P53 gene in the tumors overexpress-
ing the MDM2 p57 was not reported. Our data show that 
MDM2 p57 is the predominant isoform in cancer cells that 
have mutations in the P53 gene. However, further studies 
are required to fully  understand the  correlation  between 
the expression of the different forms of MDM2 proteins 
and the P53 status in breast cancer tumors. 
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